European Psychiatry - Volume 41 - April 2017

814 / 916

S810 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S772–S846
EV1238
Factors of premorbid period
indicating the risk of medicated
noncompliance in patients with
schizophrenia
E. Dmitrieva ∗, E. Kornetova
Mental Health Research Institute, Tomsk National Research Medical
Center, Russian Academy of Sciences, Endogenous Disorders
Department, Tomsk, Russia
∗ Corresponding author.
Background Methods of assessment of medicated compliance are
based upon preceding experience of taking therapy and cannot be
applied at the first admission.
Objective To investigate premorbid characteristics in schizo-
phrenic patients and reveal the factors indicating noncompliance.
Methods We used medical record background, interview, Med-
ical Compliance Prediction Scale for Psychiatry for evaluation of
the level of compliance, programSTATISTICA10 for identification of
the average level of compliance in the subgroups of each factor by
Kruskal–Wallis test and revealing those subgroups for each factor
where the average level of compliancewas statistically significantly
lower (P < 0.05).
Results We examined 120 patients (status corresponded to the
ICD-10 diagnostic criteria for schizophrenia, age–18 and older,
duration of the disease–5 years and more, patients taking typical
or atypical antipsychotics or combined therapy) according to fac-
tors of premorbid period such as gender, family history of mental
disorders, personality traits, nurture in the family, education level,
marital status; substance use, age at the onset of disease.
Conclusions Level of compliance was lower in subgroups of men,
patients having several relatives with mental disorders, patients
having personality with predominance of irritable and impulsive
traits, patients with neglect in parental families, patients with edu-
cation level lower than high school and with education level higher
than bachelor; patients not working or studying to onset of disease;
patients who were divorced or widowed; patients living alone;
patients using psychoactive substances; patients aged 21 years and
older to the onset of disease.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1239
Objectively measurable
equilibriometric locomotor ataxia in
schizophrenia
G. Dzhupanov ∗, S. Haralanov , P. Terziivanova , E. Haralanova
Medical University, Sofia, Department of Psychiatry and Medical
Psychology, Sofia, Bulgaria
∗ Corresponding author.
Introduction The basic role of cerebellar dysfunctions in
schizophrenia pathophysiology is already well-known. Impor-
tantly, cerebellar signs such as gait and balance coordination
deficits are objectively manifested and measurable. However, both
early detection and treatment monitoring of the illness are still-
based mainly on subjective psychopathological symptoms.
Aims To introduce an objective and quantitative approach to the
cerebellar gait and balance disorders in schizophrenia.
Methods An original (internationally patented) method for
objective equilibriometric quantification of stepping locomotion (a
kind of motion analysis system) was developed and then applied
repetitively in 230 schizophrenic patients and 230 well-matched
healthy controls.
Results Subclinical but objectively measurable equilibriometric
locomotor ataxia (ELA) was identified in a large proportion of
the investigated patients. Its severity fluctuated along with the
changes in the clinical state. As a rule, the degree of ELA transiently
increases during psychotic exacerbation and gradually returns to
its prepsychotic level during therapeutic remission. Data analy-
sis revealed that the basic (prepsychotic and postpsychotic) ELA
could be viewed as a new schizotaxic biomarker (trait-marker)
for schizophrenia, while the degree of its severity could serve as
a new objectively measurable state-marker for psychosis. Besides,
its dynamics during antipsychotic treatment might be used as an
objective measure of the therapeutic response (a kind of surrogate
pharmacodynamic biomarker).
Conclusions Objective quantification of the ELA allows for early
detection of subclinical signs of cerebellar ataxia (or schizotaxia)
in individuals at high-risk for schizophrenia, whereas in psychotic
patients it permits their objective antipsychotic-treatment moni-
toring.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1240
Metabolic health in patients with
schizophrenia – CVD risk in a
Norwegian outpatient population
J. Engh ∗, E. Andersen , E. Martinsen , J. Egeland ,
T.L. Holmen , T.T. Bigseth , G. Bang-Kittilsen
1 Vestfold Hospital Trust, Mental Health and Addiction, Tønsberg,
Norway
2 Faculty of humanities and education, University College of South
East Norway, Department of practical, physical and aesthetic
education, Vestfold, Norway
3 Institute of clinical medicine, University of Oslo, Department of
neuroscience, Faculty of medicine, Oslo, Norway
4 Vestfold Hospital Trust, University of Oslo, Mental Health and
Addiction, Department of psychology, Tønsberg, Oslo, Norway
∗ Corresponding author.
The mortality of schizophrenia patients is approximately twice
that of the general population and there is a 20% reduction in life
expectancy in this patient group. Cardiovascular disease (CVD) is
responsible for as much as 50% of the excess mortality associ-
ated with schizophrenia. One important source of the high CVD
prevalence is the cluster of metabolic characteristics defining
the metabolic syndrome (MetS: 3 or more of the following fea-
tures: abdominal obesity, high blood pressure, elevated levels of
triglycerides and fasting glucose and low levels of high-density
lipoproteins). Patients with schizophrenia seem to be undertreated
for these vascular risk factors relative to the general population.
More knowledge is needed concerning broadened risk factors of
cardiovascular disease in a representative sample of schizophrenia
patients. We conducted preliminary cross sectional analyses in a
sample of 64 consecutive outpatients with schizophrenia with a
mean age of 37 years consisting of 59% men, who were enrolled in
a treatment study. All used antipsychotics, and 71% were smok-
ers. We found that (percentage of patients under treatment for
the respective somatic condition in parenthesis) 82% were over-
weight, 49% had hypertonia (17%), 24% hyperglycemia (3%), 48%
hypertriglyceridemia and 13% hyperlipidemia (10% triglycerid or
cholesterol loweringmedication). Forty percent hadmetabolic syn-
drome compared to 11% in the normal population (Norway, age
corrected). Additionally, estimates of insulin resistance will be con-
ducted. We found that the prevalence of MetS components was
high in outpatient schizophrenia. A substantial discrepancy was
found between metabolic ill health and medication treatment of
such conditions.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.